U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Edwards SJ, Barton S, Thurgar E, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jan. (Health Technology Assessment, No. 19.7.)

Cover of Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.

Show details

Appendix 15Tornado diagrams

Tornado diagram of parameters to which the cost-effectiveness of paclitaxel plus platinum versus platinum monotherapy is most sensitive (PS network 1). pac, paclitaxel; plat, platinum; pts, patients

Image 10-108-01-fig93.jpg

Tornado diagram of parameters to which the cost-effectiveness of PLDH plus platinum versus platinum monotherapy is most sensitive (PS network 1). pac, paclitaxel; plat, platinum

Image 10-108-01-fig94.jpg

Tornado diagram of parameters to which the cost-effectiveness of PLDH plus platinum versus paclitaxel plus platinum is most sensitive (PS network 1). pac, paclitaxel; plat, platinum

Image 10-108-01-fig95.jpg

Tornado diagram of parameters to which the cost-effectiveness of PLDH versus paclitaxel is most sensitive (PS network 2). pac, paclitaxel

Image 10-108-01-fig96.jpg

Tornado diagram of parameters to which the cost-effectiveness of trabectedin plus PLDH versus paclitaxel is most sensitive (PS network 2). pac, paclitaxel; Trab, trabectedin

Image 10-108-01-fig97.jpg

Tornado diagram of parameters to which the cost-effectiveness of trabectedin plus PLDH versus PLDH is most sensitive (PS network 2). Trab, trabectedin

Image 10-108-01-fig98.jpg

Tornado diagram of parameters to which the cost-effectiveness of topotecan versus PLDH is most sensitive (platinum resistant/refractory). Top, topotecan

Image 10-108-01-fig99.jpg

Tornado diagram of parameters to which the cost-effectiveness of paclitaxel versus PLDH is most sensitive (platinum resistant/refractory). pac, paclitaxel

Image 10-108-01-fig100.jpg
Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK269553
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (8.4M)

In this Page

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...